ArticleCureus2026
TMPRSS2-ERG Fusion Identified by Comprehensive Genomic Profiling Reveals Prostatic Origin in Cancer of Unknown Primary: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer of unknown primary (CUP) comprises a heterogeneous group of malignancies in which the primary site cannot be identified despite comprehensive evaluation. Patients in the unfavorable-risk group have limited therapeutic options and typically receive empirical chemotherapy, which is associated with poor outcomes. Comprehensive genomic profiling (CGP) has emerged as a valuable tool for identifying potential therapeutic targets in advanced or rare solid tumors, including cancer of unknown primary. However, the proportion of actionable alterations remains limited, and genomic findings that do not directly inform treatment selection have received relatively little attention, despite their potential relevance for identifying the tissue of origin. We report the case of a 79-year-old man presenting with multiple lymph node metastases from an unknown primary and clinically localized prostate cancer. Comprehensive genomic profiling was performed on a metastatic lymph node specimen. Although no alterations with immediate therapeutic relevance were identified, a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.